CD4 News and Research

RSS

Tibotec, Gilead Sciences enter license agreement for new combination product of PREZISTA and cobicistat

Tibotec Pharmaceuticals today announced that it has entered into a license agreement with Gilead Sciences, Inc., for the development and commercialization of a new once-daily single tablet fixed-dose antiretroviral combination product containing Tibotec's protease inhibitor PREZISTA® (darunavir) and Gilead's cobicistat, an investigational pharmacoenhancing or "boosting" agent.

28 Jun 2011

Researchers identify how sooty mangabeys survive SIV infection

Sooty mangabeys, a type of African monkey, have intrigued scientists for years because they can survive infection by SIV, a relative of HIV, and not succumb to AIDS.

27 Jun 2011

Biotest, Abbott partner to develop and commercialize BT-061 for autoimmune diseases

Abbott and Biotest AG today announced a global agreement to develop and commercialize BT-061, a novel anti-CD4 antibody for the treatment of rheumatoid arthritis (RA) and psoriasis.

22 Jun 2011

CDT biomarker poor, inaccurate method for detecting unhealthy drinking in HIV-infected adults

Researchers from Boston University School of Medicine (BUSM) have found that among HIV-infected adults with alcohol problems, measuring their carbohydrate-deficient transferrin (CDT) biomarker was a poor and inaccurate method for detecting unhealthy drinking.

21 Jun 2011

UCLA researchers find new potential therapeutic target for preventing HIV

Specific types of "helper" T cells that are crucial to maintaining functioning immune systems contain an enzyme called PDI. This enzyme affects how proteins fold into specific shapes, which in turn influences how the T cells behave.

16 Jun 2011

International coalition launches common platform to end AIDS epidemic

An international coalition of scientists and activists today launched a common platform for ending the AIDS epidemic. Thirty years into the epidemic, as world leaders come together at the United Nations to recommit to a global AIDS response, the broad-based international coalition issued a statement calling for world leaders to support a rational, evidence-based approach to responding to AIDS.

8 Jun 2011

OncoSec announces additional evaluation of ElectroImmunotherapy Phase I trial on melanoma

OncoSec Medical Incorporated, which is developing its advanced-stage ElectroOncology therapies to treat solid tumor cancers, announced today that additional evaluation of a previous Phase I trial provided further evidence that a DNA plasmid encoded to produce IL-12 delivered by electroporation into melanoma lesions induces responses to known and novel antigens, resulting in regression of local treated lesions as well as distant untreated lesions.

7 Jun 2011

Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma

ZIOPHARM Oncology, Inc. announced today that Douglas J. Schwartzentruber, MD, FACS, of the Indiana University Health Goshen Center for Cancer Care, presented initial positive clinical results from the first-ever treatment demonstrating control over transgene encoding of a therapeutic anticancer protein in humans using a small molecule activator ligand.

7 Jun 2011

New data from Argos AGS-003, sunitinib Phase 2 combination study on RCC presented at ASCO

Argos Therapeutics today announced that new data from its Phase 2 combination study of its Arcelis immunotherapy for the treatment of renal cell carcinoma (RCC), AGS-003, in combination with sunitinib showed improvement over expectations for sunitinib alone in progression-free survival (PFS) in newly diagnosed metastatic RCC patients with unfavorable prognosis.

6 Jun 2011

Novel topically-applied molecular microbicide protects women against HIV infection

Using a technique that silences genes promoting infection, researchers have developed a novel, topically-applied molecular microbicide capable of preventing HIV transmission.

17 May 2011

Early HIV treatment can reduce transmission risk by 96%, preliminary study results show

Preliminary results from a multicountry clinical trial, sponsored by the National Institute for Allergy and Infectious Diseases (NIAID), show that HIV-positive people who take combination antiretroviral therapy (ART) can reduce the risk of transmitting the virus to their HIV-negative partners by 96 percent, U.S. researchers announced on Thursday " in what is being hailed as a breakthrough in HIV prevention," the Los Angeles Times reports.

16 May 2011

Early treatment of HIV makes infection transmission less likely: Study

“It's a game-changer,” Michel Sidibe, executive director of UNAIDS, said. “I am completely amazed.” It was noted that anti-HIV drugs called antiretroviral drugs can suppress HIV in an infected patient and also help to prevent its spread through intercourse, he said. He predicted a rethink of the strategies that have evolved since the first cases of AIDS were recorded in June 1981. “The implications are multiple,” said Mr Sidibe. “However, money will be the major challenge.”

15 May 2011

Early antiretroviral treatment can halt HIV spread in couples

A research study led by the University of North Carolina at Chapel Hill has made a major discovery in the effort to halt the spread of HIV, the virus that causes AIDS.

13 May 2011

Antiretroviral therapy can reduce risk of HIV transmission in couples

When one partner in a couple is infected with HIV and the other is not, treatment with antiretroviral drugs can dramatically lower the chances of the infected partner passing along the disease to his or her mate, a new evidence review finds.

12 May 2011

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, the Centre Léon Bérard, the major cancer research and treatment center for the Rhône-Alpes region of France, and ImmunID Technologies SAS, a diagnostic company specialized in innovative immunomonitoring tests and services, today announced initiation of a Phase IIa clinical trial that will evaluate multiple combinations of recombinant human interleukin-7, the investigational multifunctional cytokine under development by Cytheris, and a chemotherapeutic agent, XELODA, in the treatment of metastatic breast cancer.

11 May 2011

Neutralizing antibodies generated by immunization associated with protection against SIV infection

Using a monkey model of AIDS, scientists have identified a vaccine-generated immune-system response that correlates with protection against infection by the monkey version of HIV, called simian immunodeficiency virus (SIV). The researchers found that neutralizing antibodies generated by immunization were associated with protection against SIV infection.

6 May 2011

Study: HIV infection linked to increased risk of heart failure

Patients with HIV infection without a prior history of coronary heart disease may be at a higher risk of developing heart failure, according to a report in the April 25 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

26 Apr 2011

Research sheds new light on pathogenesis of diabetes

New research identifies a distinctive population of immune cells that may play a key role in the pathogenesis of diabetes.

22 Apr 2011

African AIDS drug trial stopped prematurely

One of the studies in three African countries where women were given an AIDS drug to prevent HIV infection is being stopped because the project is not working, researchers said Monday. These women on the trial were taking a daily dose of the drug Truvada or a look-alike placebo pill and had an equal chance of becoming infected. The ones taking Truvada were expected to have had a much lower infection rate.

19 Apr 2011

Increased risk of virologic failure associated with NNRTI-based regimens in HIV-1 drug resistance mutations

An analysis of data from 10 studies indicates that the presence of low frequency (also called "minority") human immunodeficiency virus type 1 (HIV-1) drug resistance mutations, particularly those involving nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance, are significantly associated with an increased risk of first-line antiretroviral treatment failure, according to an article in the April 6 issue of JAMA.

6 Apr 2011